Journal for Immunotherapy of Cancer

Article	Citations
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	301
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	191
Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	184
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy	162
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	146
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	144
Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer	138
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	131
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	128
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis	128
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	125
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	121
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	117
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	114
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	114
Commentary on oncolytic viruses: past, present, and future	111
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	109
Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies	108
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	104
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	102
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	101
iRECIST and atypical patterns of response to immuno-oncology drugs	101
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	100
Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis	100
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	98

Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	96
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	95
Serotonin transporter SERT: a novel immune checkpoint for CD8 + T cell antitumor therapy	92
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	91
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	91
Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment	90
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	88
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	87
Biomarkers for response to TIL therapy: a comprehensive review	87
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	85
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	83
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity	83
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	83
Is immunotherapy safe and effective in patients with VEXAS syndrome?	82
Differential phagocytosis induces diverse macrophage activation states in malignant gliomas	82
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade	82
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	81
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	80
T-cell tolerant fraction as a predictor of immune-related adverse events	80
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells	79
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwid	79
Single-cell analysis reveals clonally expanded tumor-associated CD57 + CD8 T cells are enriched in the periphery of patients with metastatic urotheli	78
TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how	77
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047	75
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	75
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment	75
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	75
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	74
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	74
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	73
SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication	72
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	72
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	72
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control	71
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies	71
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study	70
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells	70
Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials	70
Correction: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages	70
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D	69
Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy	68
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors	68
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis	68
Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC	67
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs	66
Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy	66
Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression	66
In memoriam: Soldano Ferrone, MD, PhD (1940–2023)	65
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial	65
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0	65

Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms’ tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine	65
Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)	65
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia	64
Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma	64
Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for p	64
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models	64
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species	64
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation	63
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16	63
CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer	63
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix	62
Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition	62
SIGLEC11 promotes M2 macrophage polarization through AKT–mTOR signaling and facilitates the progression of gastric cancer	62
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy	62
Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL	61
Sulforaphane activates CD8+ T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’	61
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses	61
Dual regulation of CXCR6 + CD8 + T cells modulates cytotoxic and exhaustion-associated programs du	60
Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer	60
PD-L1 gene amplification and focality: relationship with protein expression	59
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch	59
Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer	59
CD33 KO -CD33-mesothelin Loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia	59
Correction: Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment	58
Systemic STING agonist therapy drives expression of interferon stimulated genes and downstream production of cytokines in dogs with solid tumors	58
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma	57
Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination	57
Apoptosis: a Janus bifrons in T-cell immunotherapy	57
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma	57
Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy	56
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies	56
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity	56
Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment	56
Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer	56
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechalle	56
Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity	56
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications	56
Targeting immunosuppressive macrophages by CSRP2-regulated CCL28 signaling sensitizes hepatocellular carcinoma to lenvatinib	56
Modulating lipid metabolism improves tumor immunotherapy	56
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy	55
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function	55
TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion	54
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes	54
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy	54
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy	53
Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy	53
Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity	53
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells	53
Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy	52
PD-L1-targeted PET imaging for non-invasive assessment of immunotherapy response in lung cancer	52
Author response to Zhang et al	52
Correction: Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers	52
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens	52
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)	52
Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance	52
Correction: Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel	52
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)	52
Advancing ICOS agonism in solid tumors: lessons from INDUCE-1	52
Correction: Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma	52
L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression	51
Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity	51
Correction: Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody	51
Correction: Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events	51
Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma	50
Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system	50
Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy	50
Id-neoantigen vaccine induces therapeutic CD8+ T cells against multiple myeloma: H chain-loss escapees cause FLC MM	50
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors	50
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders	49
Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models	49
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade	49
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors	49
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report	49
Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer	48
Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refrac	48
Serotonin receptor 5-HT 2A as a potential target for HCC immunotherapy	48
Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis	48
Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity	47
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms	47
Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma	47

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors	47
Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases	47
Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer	47
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome	47
Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors	46
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al	46
Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation	46
Rescuing natural killer cells from the cancer wilderness	46
PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors	46
Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer	46
Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization	46
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial	46
Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses	45
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors	45
Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models	45
Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience	44
Novel oncolytic adenovirus-based PEPvIII vaccine displays a super antitumor effect in glioma models	44
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer	44
Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells	44
The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer	44
Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma	44
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?	43
Potentiation of cancer immunogenicity by targeting PARP	43
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade	43
Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a ph	43
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity	43
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex	43
Spatial immune remodeling of the liver metastases: discovering the path to antimetastatic therapy	42
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma	42
Targeting SPP1 + TAMs associated with liver metastasis reverses immunosuppression and synergizes with immunotherapy in col	42
Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation	42
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC	42
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma	42
Guidelines for immunological analyses following focused ultrasound treatment	41
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy	41
Correction: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy	41
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG	41
Correction: MRI techniques for immunotherapy monitoring	41
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR	40
CD56bright cytokine-induced memory-like NK cells and NK-cell engagers synergize against non-small cell lung cancer cancer-stem cells	40
Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’	40
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma	40
Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS	40
Letter to the editor: transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study	40
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes	40
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer	40
AGPAT3 reshapes tumor cell vulnerability to IFNγ-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling	40
Polymorphonuclear myeloid-derived suppressor cells and phosphatidylinositol-3 kinase gamma are critical to tobacco-mimicking oral carcinogenesis in mice	39
Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia	39
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins	39
Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?	39
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase	39
Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-α triggers tumorigenic inflammation in neuroblastoma	39
Vaccines for immunoprevention of DNA mismatch repair deficient cancers	39
Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma	39
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma	39
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment	39
Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy	38
In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade	38
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells	38
Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression	38
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies	38
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma	38
ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers	38
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive	38
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab	38
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression	38
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer	38
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses	38
Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin	38
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis	38
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors	38
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C	38
Inhibition of osteosarcoma lung metastases by β-glucan and CD40 agonist is mediated by activation of macrophages and NK cells	38
Specific inhibitor to KRASG12C induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy	38
Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry	38
No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC	37
Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer	37
Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer	37
MCT4 blockade increases the efficacy of immune checkpoint blockade	37
Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8 + T cells	37
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial	37
Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy	37
Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use	37
Constructing the cure: engineering the next wave of antibody and cellular immune therapies	37
Selective BCL-2 inhibitor triggers STING-dependent antitumor immunity via inducing mtDNA release	37
Therapeutic inhibition of USP7 promotes antitumor immune responses	37
Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study	37
Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma	36
Correction: Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+ TILs based on BRCA1/2 mutation status in epithelial ovarian cancers	36
Correction: Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis	36
Non-synergy of PD-1 blockade with T-cell therapy in solid tumors	36
Clinical-radiomics nomogram integrating lymph node radiomic features to predict immunotherapy response in advanced biliary tract cancers	36
Correction: Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study	36
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy	36